MedTrace Logo

Effects of Remote Ischemic Pre-Conditioning in Moyamoya Disease Patients

NCT04064658 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 328

Last updated 2019-09-19

No results posted yet for this study

Summary

In the present study, investigators evaluated whether RIPC reduce the major neurological complications in adult moyamoya disease patients undergoing encephaloduroarteriosynangiosis (EDAS).

Conditions

  • Moyamoya Disease
  • Remote Ischemic Preconditioning

Interventions

PROCEDURE

Remote ischemic preconditioning

Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.

PROCEDURE

Sham remote ischemic preconditioning

Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.

PROCEDURE

Encephaloduroarteriosynangiosis

Encephaloduroarteriosynangiosis is an indirect revascularization surgery of moyamoya disease

Sponsors & Collaborators

  • Peking University International Hospital

    collaborator OTHER

  • Beijing Tiantan Hospital

    lead OTHER

Principal Investigators

  • Yuanli Zhao, MD · Beijing Tiantan Hospital

  • Rong Wang, MD · Beijing Tiantan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2023-10-01
Completion
2024-04-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04064658 on ClinicalTrials.gov